Oppenheimer & Co. Inc. reduced its stake in shares of CME Group Inc. (NASDAQ:CME) by 5.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 38,525 shares of the company’s stock after selling 2,217 shares during the period. Oppenheimer & Co. Inc.’s holdings in CME Group were worth $4,026,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in CME. Bronfman E.L. Rothschild L.P. raised its position in CME Group by 4.0% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 1,155 shares of the company’s stock worth $121,000 after buying an additional 44 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of CME Group by 447.6% in the second quarter. Tower Research Capital LLC TRC now owns 1,621 shares of the company’s stock worth $157,000 after buying an additional 1,325 shares during the period. Advisors Preferred LLC purchased a new position in shares of CME Group during the third quarter worth approximately $180,000. Warren Averett Asset Management LLC purchased a new position in shares of CME Group during the third quarter worth approximately $211,000. Finally, Parametrica Management Ltd purchased a new position in shares of CME Group during the second quarter worth approximately $212,000. Institutional investors and hedge funds own 79.55% of the company’s stock.

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

CME Group Inc. (NASDAQ:CME) traded up 0.71% on Tuesday, reaching $112.67. 957,253 shares of the company’s stock traded hands. CME Group Inc. has a 52 week low of $81.87 and a 52 week high of $117.80. The firm has a market capitalization of $38.23 billion, a P/E ratio of 26.26 and a beta of 0.81. The stock has a 50-day moving average of $107.19 and a 200 day moving average of $102.98.

CME Group (NASDAQ:CME) last released its earnings results on Thursday, October 27th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.04 by $0.01. CME Group had a net margin of 41.54% and a return on equity of 6.90%. The business had revenue of $842 million for the quarter, compared to analysts’ expectations of $855.94 million. During the same period last year, the company earned $1.02 earnings per share. The company’s quarterly revenue was down 1.0% on a year-over-year basis. On average, equities analysts expect that CME Group Inc. will post $4.35 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 28th. Investors of record on Friday, December 9th will be given a $0.60 dividend. The ex-dividend date is Wednesday, December 7th. This represents a $2.40 annualized dividend and a dividend yield of 2.13%. CME Group’s dividend payout ratio is presently 55.94%.

COPYRIGHT VIOLATION WARNING: “CME Group Inc. (CME) Shares Sold by Oppenheimer & Co. Inc.” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2016/11/29/cme-group-inc-cme-shares-sold-by-oppenheimer-co-inc.html.

CME has been the topic of a number of analyst reports. Zacks Investment Research raised shares of CME Group from a “hold” rating to a “buy” rating and set a $116.00 target price on the stock in a research note on Thursday, August 4th. Deutsche Bank AG lifted their target price on shares of CME Group from $111.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, August 5th. Jefferies Group lifted their target price on shares of CME Group from $112.00 to $118.00 and gave the stock a “buy” rating in a research note on Wednesday, August 31st. JPMorgan Chase & Co. set a $116.00 target price on shares of CME Group and gave the stock a “buy” rating in a research note on Monday, September 12th. Finally, Royal Bank Of Canada reduced their target price on shares of CME Group from $97.00 to $92.00 and set an “underperform” rating on the stock in a research note on Friday, October 28th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $102.89.

In related news, CEO Terrence A. Duffy sold 17,375 shares of the firm’s stock in a transaction that occurred on Friday, November 25th. The shares were sold at an average price of $112.58, for a total value of $1,956,077.50. Following the sale, the chief executive officer now directly owns 127,739 shares of the company’s stock, valued at $14,380,856.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Bryan T. Durkin sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $107.75, for a total transaction of $1,616,250.00. Following the completion of the sale, the insider now directly owns 63,967 shares in the company, valued at $6,892,444.25. The disclosure for this sale can be found here. 0.61% of the stock is currently owned by corporate insiders.

About CME Group

CME Group Inc is a provider of products across all major asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals. The Company’s products include both exchange-traded and privately negotiated futures and options contracts and swaps. The Company connects buyers and sellers together through its CME Globex electronic trading platform across the globe and its open outcry trading facilities in Chicago and New York City.

5 Day Chart for NASDAQ:CME

Receive News & Stock Ratings for CME Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group Inc. and related stocks with our FREE daily email newsletter.